ArticleThe oncologist2023

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.

Bradley McGregor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.